Patents Examined by Jeffrey S. Lundgren
  • Compound for improving L-arginine bioavailability
    Patent number: 11655210
    Abstract: The present application relates to a compound which may be useful for mediating NO production and improving L-arginine bioavailability in a subject. Pharmaceutical compositions comprising the compound and methods of using the compound are also provided.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: May 23, 2023
    Assignee: The General Hospital Corporation
    Inventors: Maurizio Fava, Xudong Huang
  • Tetrahydroquinazoline derivatives as selective cytotoxic agents
    Patent number: 11648250
    Abstract: The present disclosure is directed to tetrahydroquinazoline derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: May 16, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Antonella Converso, Abdellatif El Marrouni, Anthony W. Shaw, David N. Hunter, Ashley Forster, Cheng Wang, Yunlong Zhang
  • Ambrisentan for use in the treatment of acute renal failure
    Patent number: 11642307
    Abstract: Ambrisentan and formulations thereof for use in the treatment and prevention of acute renal failure associated with renal vasoconstriction.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: May 9, 2023
    Assignee: Noorik Biopharmaceuticals AG
    Inventor: Iker Navarro
  • EZH2 inhibitors for treating lymphoma
    Patent number: 11642347
    Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: May 9, 2023
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Heike Keilhack, Sarah K. Knutson, Danielle Johnston Blackwell, Larisa Reyderman, Lone Ottesen
  • Aqueous compositions comprising bilastine and mometasone
    Patent number: 11642309
    Abstract: The invention relates to an aqueous pharmaceutical composition comprising: a) bilastine or a pharmaceutically acceptable salt or solvate thereof, b) mometasone, or a pharmaceutically acceptable derivative thereof, c) a suspending agent, and d) 2-hydroxypropyl-?-cyclodextrin; wherein the pH of the aqueous pharmaceutical composition is between 3.5 and 5.5, and wherein the content of 2-hydroxypropyl-?-cyclodextrin is less than 8.5% by weight. The invention also relates to said compositions for use in the treatment and/or prevention of a disorder or disease susceptible to amelioration by antagonism of H1 histamine receptor and/or of a corticosteroid-responsive disease through nasal administration. The invention also relates to a process for preparing the aqueous pharmaceutical composition above mentioned.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: May 9, 2023
    Assignee: FAES FARMA, S.A.
    Inventors: Gonzalo Hernández Herrero, Ana Gonzalo Gorostiza, Neftalí García Domínguez, Arturo Zazpe Arce, Pablo Morán Poladura, Tania González García
  • Rucaparib, Talazoparib, Veliparib, Olaparib and AZD 2461 for treating impaired skin wound healing
    Patent number: 11638709
    Abstract: The present invention relates to Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib, and/or AZD 2461, or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with Rucaparib and/or Talazoparib and/or Veliparib and/or Olaparib and/or AZD 2461, and kits and kits-of-part related thereto.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: May 2, 2023
    Assignee: AKRIBES BIOMEDICAL GMBH
    Inventors: Barbara Wolff-Winiski, Anton Stütz, Petra Dörfler
  • Nasal formulations of metoclopramide
    Patent number: 11628150
    Abstract: Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: April 18, 2023
    Assignee: Evoke Pharma, Inc.
    Inventors: Matthew J. D'Onofrio, David A. Gonyer, Shirish A. Shah, Stuart J. Madden
  • CCL5 inhibitors
    Patent number: 11628154
    Abstract: Compounds, pharmaceutically acceptable salts, esters, prodrugs, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL5 on mammalian cells, as well as methods of treatment for diseases involving the increased biological activity of CCL5.
    Type: Grant
    Filed: August 19, 2022
    Date of Patent: April 18, 2023
    Assignee: LAPKO INC
    Inventor: Bruce Kovacs
  • Treating extrapyramtdal syndrome using trapidil
    Patent number: 11628170
    Abstract: Disclosed herein are methods, pharmaceutical combinations, or kits for the prevention or treatment of extrapyramidal syndromes, for example, dyskinesia, dystonia, akathisia, or drug-induced Parkinsonism, with the administration of a therapeutic effective amount of Trapidil, a derivative, a metabolite, a prodrug, an analog, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: April 18, 2023
    Assignee: SINOPIA BIOSCIENCES, INC.
    Inventor: Aarash Bordbar
  • Spirocyclic compounds
    Patent number: 11623929
    Abstract: The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: April 11, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Roger Norcross, Philipp Schmid
  • Hybrid mycelial cellulose sheet and preparation thereof
    Patent number: 11623980
    Abstract: A leather-like hybrid mycelial cellulose sheet and production thereof. Precise selection of mushroom species and reagents allows for production at low pH, thereby resulting in a strong, flexible, and dry leather-like material suitable for application in various industries.
    Type: Grant
    Filed: May 24, 2022
    Date of Patent: April 11, 2023
    Assignee: VU MON TECHNICAL AND TECHNOLOGY CO., LTD.
    Inventors: Thuong Thi Lien Nguyen, Chanh Minh Nguyen
  • Methods of treating oral mucositis
    Patent number: 11612608
    Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: February 27, 2020
    Date of Patent: March 28, 2023
    Assignee: galera labs, llc
    Inventors: David M. Rothstein, Chris Murphy, Vivien Wong, Glenn Kazo
  • Oral care product and methods of use and manufacture thereof
    Patent number: 11612553
    Abstract: This invention relates to oral care compositions comprising an effective amount of a basic amino acid in free or salt form, together with an antibacterial agent, and to methods of using and of making such compositions.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: March 28, 2023
    Assignee: Colgate-Palmolive Company
    Inventors: Michael Prencipe, Ravi Subramanyam, Sarita V. Mello, Donghui Wu, Suman Chopra, Andre M. Morgan, Diane Cummins, Richard J. Sullivan, Ralph Peter Santarpia, III, Lynette Zaidel, Qin Wang, Gary Edward Tambs, Virginia Monsul Barnes, Rajnish Kohli, Richard Scott Robinson, Sergio Leite, Eric A. Simon
  • Method for inducing tumor regression
    Patent number: 11607455
    Abstract: Methods for treating cancer and/or inducing tumor regression in mammals (e.g., humans) by increasing the metabolism of the mammal, administering a BA dye to the mammal, and thereafter exposing the tumor to actinic light for activation of the BA dye.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: March 21, 2023
    Assignee: VeroScience LLC
    Inventor: Anthony H. Cincotta
  • Therapeutical methods, formulations and nutraceutical formulations
    Patent number: 11607406
    Abstract: Compositions and methods are described for the prevention, treatment, or management of sexual dysfunction, such as premature ejaculation. The method comprises administering an effective amount of tetrahydropalmatine or its derivative or Rhizoma Corydalis extract containing composition to a human male on an as-needed basis shortly before sexual activity to delay ejaculation.
    Type: Grant
    Filed: March 1, 2020
    Date of Patent: March 21, 2023
    Inventor: Tianxin Wang
  • Manufacturing method for and insecticidal compositions comprising thiocyclam hydrochloride
    Patent number: 11591309
    Abstract: A method for manufacturing an insecticidal compound and insecticidal compositions comprising the insecticidal compound and methods of use are presented herein. The manufacturing method presented herein allows for a high purity grade of thiocyclam hydrochloride to be synthesized. The insecticidal compositions comprising the thiocyclam hydrochloride can be used for prevention of crop destruction by insects. The use of thiocyclam hydrochloride in insecticidal compositions as described herein can achieve greater efficacy than previously known insecticides, by eliminating the insect pests more reliably and efficiently.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: February 28, 2023
    Assignee: ARYSTA LIFESCIENCE NORTH AMERICA, LLC
    Inventors: Cameron S. Gibb, Christopher L. Larson, Mark T. Singleton, Kamal L. Kataria, Samantha Besse, Joseph A. Moore, III, Thomas C. Lovelace, Chandra S. Kanugala, Srinivas Vollala, Balraju Vadla
  • Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
    Patent number: 11590135
    Abstract: The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: February 28, 2023
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Joseph K. Belanoff, Hazel Hunt, Onno C. Meijer, José van den Heuvel
  • Composition for relieving itch or irritation of skin, comprising thymol trimethoxycinnamate
    Patent number: 11583512
    Abstract: The present disclosure discloses a composition for relieving skin itch or irritation, which contains thymol trimethoxycinnamate or a stereoisomer, salt, hydrate or solvate thereof as an active ingredient, and a method for relieving skin itch or skin irritation by administering the composition to a subject in need of reliving of skin itch or irritation. The composition according to an aspect of the present disclosure has a superior effect of relieving skin itch or skin irritation by inhibiting the voltage-gated sodium channel Nav1.7 without side effects.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: February 21, 2023
    Assignee: Amorepacific Corporation
    Inventors: Yeonsu Jeong, Bongsoo Pi
  • NTRK1 fusion molecules and uses thereof
    Patent number: 11578372
    Abstract: Novel NTRK1 fusion molecules, detection reagents, and uses and kits for evaluating, identifying, assessing and/or treating a subject having a cancer are disclosed.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: February 14, 2023
    Assignee: Foundation Medicine, Inc.
    Inventors: Matthew J. Hawryluk, Doron Lipson, Vincent A. Miller, Philip James Stephens
  • Target genes in MYC-driven neoplasia
    Patent number: 11576912
    Abstract: Methods are provided for treating a subject having a MYC-driven neoplasia. Aspects of the methods include administering to the subject an amount of an inhibitor of a target gene effective to treat the subject for the MYC-driven neoplasia. Methods are also provided for identifying a MYC-dependent target gene in a MYC-driven neoplasia. Aspects of the method include identifying the MYC-dependent target gene based on a phenotype detected in a first tumor cell line conditionally expressing MYC that is absent or quantitatively different in a second tumor cell line conditionally repressing MYC when the two cell lines are contacted with a CRISPR-based gene silencing agent. Kits and cell lines for practicing the methods of the disclosure are also provided.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: February 14, 2023
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Anja Deutzmann, Dean W. Felsher, Yulin Li